Drug Profile
VM 1010
Alternative Names: VM-1010Latest Information Update: 11 Sep 2023
Price :
$50
*
At a glance
- Originator Viriom
- Class Antivirals; Small molecules
- Mechanism of Action Hepatitis B virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hepatitis B
Most Recent Events
- 11 Sep 2023 Discontinued - Preclinical for Hepatitis B in Russia (unspecified route) (Viriom pipeline, September 2023)
- 28 Aug 2019 No recent reports of development identified for preclinical development in Hepatitis-B in Russia
- 02 Jul 2019 Viriom enters into a licensing agreement with Lloyds Pharma for elsulfavirine and other drugs from Viriom HIV and Hepatitis B portfolio in Indonesia